Acceleron Announces Clinical Presentations on Luspatercept at the 22nd Congress of the European Hematology Association
May 18 2017 - 7:00AM
Business Wire
– Presentations to highlight efficacy, duration
of response, and long-term safety results from ongoing Phase 2
studies with luspatercept in myelodysplastic syndromes and
beta-thalassemia –
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage
biopharmaceutical company focused on the discovery, development and
commercialization of innovative therapeutics to treat serious and
rare diseases, today announced that two abstracts on luspatercept
will be presented at the 22nd Congress of the European Hematology
Association (EHA) in Madrid, Spain on June 22-25, 2017.
Luspatercept is being developed as part of the global collaboration
between Acceleron and Celgene.
The oral and poster presentations will include efficacy,
duration of response, and long-term safety results from the ongoing
Phase 2 studies with luspatercept in myelodysplastic syndromes
(MDS) and beta-thalassemia. The presentations at the conference
will include updated information beyond that included in the
abstracts available online on the EHA conference website. The
beta-thalassemia presentation will review results updated from the
ASH 2016 presentation in December and the MDS presentation will
highlight results updated from the recent International Symposium
on MDS earlier this month.
Oral
presentation
Title: Luspatercept Increases
Hemoglobin and Decreases Transfusion Burden in Adults with
Beta-Thalassemia (Abstract: S129)
Session: Thalassemia Date: Friday, June 23rd Time: 11:45 a.m. CEST
(IFEMA, Room N105)
Poster
presentation
Title: Luspatercept Increases
Hemoglobin and Reduces Transfusion Burden in Patients
withLower-Risk Myelodysplastic Syndromes (MDS): Long-Term Results
from Phase 2 PACE-MDS Study (Abstract: P666)
Session: Myelodysplastic Syndromes – Clinical 2 Date: Saturday,
June 24th Time: 5:30 - 7:00 p.m. CEST (IFEMA, Poster Area, Hall 7)
The luspatercept clinical poster and slides from the oral
presentation will be available immediately following the
presentations at the conference in the “Science” section on
Acceleron’s website, www.acceleronpharma.com.
About Luspatercept
Luspatercept is a modified activin receptor type IIB fusion
protein that acts as a ligand trap for members in the transforming
growth factor-beta superfamily involved in the late stages of
erythropoiesis (red blood cell production). Luspatercept regulates
late-stage erythrocyte (red blood cell) precursor cell
differentiation and maturation. This mechanism of action is
distinct from that of erythropoiesis stimulating agents (ESAs),
which stimulate the proliferation of early-stage erythrocyte
precursor cells. Acceleron and Celgene are jointly developing
luspatercept as part of a global collaboration. Phase 3 clinical
trials are underway to evaluate the safety and efficacy of
luspatercept in patients with myelodysplastic syndromes (the
“MEDALIST” study) and in patients with beta-thalassemia (the
“BELIEVE” study). For more information, please visit
www.clinicaltrials.gov.
About Acceleron
Acceleron is a clinical stage biopharmaceutical company focused
on the discovery, development and commercialization of innovative
therapeutics to treat serious and rare diseases. Its pioneering
research platform leverages the powerful biology behind the body’s
ability to rebuild and repair its own cells and tissues. This
approach to drug discovery has generated four therapeutic
candidates that are currently in clinical trials. The Company’s
lead therapeutic candidate, luspatercept, is being evaluated in
Phase 3 studies for the treatment of the hematologic diseases
myelodysplastic syndromes (MDS) and beta-thalassemia under a global
partnership with Celgene Corp. Acceleron is also advancing clinical
programs in the fields of oncology and neuromuscular diseases and
has a comprehensive preclinical research effort targeting fibrotic
and other serious diseases.
For more information, please visit www.acceleronpharma.com.
Follow Acceleron on social media: @AcceleronPharma and
LinkedIn.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170518005349/en/
Acceleron Pharma Inc.Todd James, IRC, 617-649-9393Senior
Director, Investor Relations and Corporate
CommunicationsorMedia:BMC CommunicationsBrad Miles,
646-513-3125
Acceleron Pharma (NASDAQ:XLRN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Acceleron Pharma (NASDAQ:XLRN)
Historical Stock Chart
From Sep 2023 to Sep 2024